公司資料
Hepion Pharmaceuticals 股價、新聞與催化劑
- 股票代碼:
- HEPA
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
0.07 USD (+3.68%)
收盤價
最後更新: 2026年9月17日
—
市值
股價為何變動
截至 2026年9月17日，HEPA 上漲 3.68%，收於 $0.0717。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
業務概覽
Hepion Pharmaceuticals was a liver-disease biotechnology company focused on mitochondrial dysfunction and NASH-related biology before its restructuring and decline. Its legacy centered on a difficult metabolic-liver story.
所在地與產業分類
Headquartered in the United States and listed on NASDAQ before restructuring, Hepion sat in specialty biotechnology.
商業模式特徵
The company depended on clinical validation, target biology, and the ability to translate liver-science into durable value.
生技產業定位
Hepion belongs to the historical liver-biotech category rather than the current live public-company set.
未來催化劑
- Hepion’s catalysts are HBV / liver-disease programs and any strategic update that clarifies the company’s direction. The market will want a clearer path before giving the story more credit.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。